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We performed a nation-wide study to determine the distributions of the signs and 
clinical markers of systemic lupus erythematosus (SLE) and identify any patterns in 
their distributions to allow patient subclassification. We obtained 256,999 patient-year 
records describing the disease statuses of SLE patients from 2003 to 2010. Of these, 
14,779 involved patients diagnosed within the last year, and 242,220 involved patients 
being followed-up. Along with basic descriptive statistics, we analyzed the effects of 
sex, age, and disease duration on the frequencies of signs in the first year and follow-up 
years. The patients and major signs were clustered using the Ward method. The female 
patients were younger at onset. Renal involvement and discoid eczema were more 
frequent in males, whereas arthritis, photosensitivity, and cytopenia were less. 
Autoantibody production and malar rash were positively associated with young age, and 
serositis and arthritis were negatively associated. Photosensitivity was positively 
associated with a long disease duration, and autoantibody production, serositis, and 
cytopenia were negatively associated. The SLE patients were clustered into sub-groups, 
as were the major signs. We identified differences in SLE clinical features according to 





Systemic lupus erythematosus (SLE) is an autoimmune disorder that involves multiple 
organs and can lead to severe complications including cerebral infarction, myocardial 
infarction, infection, renal failure and a poor prognosis1-4. SLE is characterized by the 
heterogeneity of its clinical features, and we have yet to fully understand this 
heterogeneity, which is one of the reasons why classification criteria for SLE5 were 
developed, and new criteria were recently proposed6.  
 
Epidemiological studies of SLE 
Epidemiological studies of SLE can be classified into two types. The first type involves 
studies on relatively detailed issues, including the clinical features of SLE, that only 
included a limited number of patients. The second type involves studies on limited 
epidemiological indices, such as the incidence and prevalence of the condition, that 
included many registrants. Most of the first type of studies were hospital-, clinic- or 
limited region-based studies with less than 1000 SLE patients 7-11, although some of 
these studies recruited participants from multiple regions within a nation12. There have 
only been two national registry-based studies of SLE, which were performed in Taiwan 
and Japan13, 14. The sample sizes of these two studies were 22,182 and 21,405, 
respectively. SLE is three to 10 times more common in females than in males 15.  The 
age-at-onset of SLE peaks from 15 to 30, and the female:male ratio has been reported to 
be highest in individuals of reproductive age and decreases in adolescence and old age16. 
While some European studies have reported differences in the age-at-onset between 
males and females17, a relatively large study involving 1,790 cases from China did not 
detect a significant difference in the mean onset age between the sexes18. Thus, it is 
unclear whether there is no difference in the onset age of SLE between males and 
females or whether such differences are only observed in Europe.  
 
Signs and clinical markers of SLE 
SLE produces a wide range of clinical signs, including physical signs and laboratory 
findings. Various reports have detected associations between the clinical features of SLE 
and age/sex, either at disease onset or throughout the clinical course of the condition. 
Thus, these reports suggested that age and/or sex can affect the signs of SLE. Efforts 
have been made to identify subgroups of SLE based on clinical manifestations19, 20. 
However, limited power of previous reports made it difficult to draw conclusions. A 
detailed analysis of the clinical features of SLE in a large-scale study would increase 
our understanding of the clinical heterogeneity of SLE.  
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Here, we performed a nationwide surveillance study of patients with SLE in Japan to 
characterize the epidemiological and clinical features of SLE. As far as we know, this is 
the largest such study to have ever been conducted.  
 
Patients and Methods 
SLE patient registration 
In Japan, a total of 56 diseases are defined as “Nanbyo (Intractable Disease)” and 
subjected to a questionnaire about their clinical status and history, which is filled in by 
the clinician providing their care, during registration. The clinicians are not limited to 
specialists for the diseases. The registered information is used for making decisions by 
experts on the public financial support provided for their medical care. Each patient is 
enrolled as a new registrant in the first year after their diagnosis, and their registration is 
renewed annually by different forms from the first ones (follow-up registry). SLE is one 
of these “Nanbyo”. This registry-based financial support system is well known 
throughout the country, and Japanese public health departments and healthcare 
professionals believe that the vast majority of patients with the diseases that receive 
medical care are registered annually. Clinical information in the questionnaire for SLE 
forms was listed in Supplementary Table 1.  
We obtained text files electronically converted from nationwide registry data about SLE 
in Japan from 2003 to 201014. Although the text files did not cover the all registrants, in 
total, 14,779 new registries were obtained from 2003 to 2010 and we adopted 2009 
(44,249 patients), which covered the largest parts of annual total registries (81.2%) as a 
year with representative follow-up data after we found that each year’s follow-up 
registries displayed similar basic statistics. For new registries, we omitted suspected 
duplicate registries and identified 14,030 registrants as novel for the purposes of this 
study. We extracted 9,374 registries for which information about disease onset was 
available and for which it could be confirmed that disease onset had occurred within the 
last year. Schematic images of quality control of dataset were illustrated in 
Supplementary Figure 1. We evaluated two patient groups, the first group, which was 
collected from 2003 to 2010, consisted of patients who had been diagnosed with SLE 
within the last year, and the other group consisted of all patients in the representative 





We extracted information about the patients’ clinical features including the 11 major 
signs included in the American College of Rheumatology (ACR) classification5, age, 
sex, age at diagnosis, and complications (infection, bone necrosis, compression fracture 
of bone, gastric ulcers, myocardial infarction, and cerebral infarction) from the registry 
for all registrants. Some items including information about anti-nuclear antibody (ANA) 
positivity, anti-sm antibody positivity, anti-ds DNA antibody positivity, the occurrence 
of biological false-positives on the syphilis test, lupus anti-coagulant positivity, and 
anti-cardiolipin antibody positivity were only available for the novel group 
(Supplementary Table 1).  
 
Sex ratio 
The female:male ratio was estimated in the all SLE group.  
 
Age distribution of SLE patients 
Age-at-onset was compared between males and females in the novel SLE and all SLE 
groups. The significance of the difference was tested by logistic regression analysis. 
 
Analysis of SLE signs and clinical markers in patients with SLE  
The frequencies of SLE signs and clinical markers were analyzed in the novel and all 
SLE groups.  The effects of age, sex, and disease duration were assessed separately 
and in combination by multiple logistic regression analysis. Clustering of the major 
signs and patients was performed in 6,637 patients in the novel SLE group for whom 
data regarding the 11 major signs and clinical markers were available and 10,000 
randomly selected patients in the all SLE group for whom data regarding the 10 major 
signs and clinical markers other than ANA were available (Supplementary Figure 1). 
The associations between complications and the patients’ basic information, SLE signs 
and clinical markers were also analyzed. We regarded autoantibody positivity at any 
point during the disease course as positivity.   
 
Statistical analysis 
Statistical analyses were performed using the R or SPSS (ver18) software. 
 
Results 
Female Ratio of SLE 
The female:male ratio was 8.14 in the all SLE group and was comparable to those 
described in previous reports (8.1-12.5)21-23. A comparison of the age distributions of the 
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male and female SLE patients in the all SLE group showed that the females were 
younger than the males (p=0.00031, Figure 1A).  The females were also younger at 
onset than the males (p=4.1x10-62, Figure 1B).  
 
Prevalence of clinical features and the effects of age and sex on them in the all SLE 
group 
The prevalences of the 10 major signs of SLE (as outlined by the ACR, except for ANA 
positivity) varied (Figure 2A, Supplementary Table 2). Cytopenia and arthritis were the 
two most common signs, and serositis was the least common sign. The frequencies of 
some of the 10 SLE signs differed markedly between males and females (Figure 2B). 
An analysis of the effects of age on the frequencies of these signs revealed four patterns, 
increases with age, decreases with age, a U-shaped age distribution (lowest in middle 
aged subjects), and an inverse-U shaped age distribution (highest in middle aged 
subjects) (Figure 2C). An analysis of the effects of disease duration on the frequencies 
of these signs revealed that most of them were frequently observed in the short duration 
after onset. The signs’ disease duration-based frequency patterns were similar to their 
age-based patterns. Photosensitivity was the only sign associated with a long disease 
duration (Figure 2D). Discoid eczema was the only sign that was not associated with 
disease duration. The detailed results are shown in Supplementary Figure 2 and 
Supplementary Table 3, and further analyses of the detailed signs of SLE are shown in 
the Supplementary note and Supplementary Figure 3. 
 
Prevalence of signs and clinical markers and the effects of age and sex on them in 
the novel SLE group  
The prevalence of the major signs of SLE also varied in the novel SLE patients, and the 
order of the signs’ frequencies (i.e., from highest to lowest) was different from that 
observed in the all SLE group (Figure 3A and Supplementary Table 2). Except for 
cytopenia, all of the SLE major signs were affected by sex in the same manner as was 
observed in the all SLE group according to multiple logistic regression analysis (Figure 
2B and 3B and Supplementary Figure 4A). The associations between age and the SLE 
signs differed between the novel and all SLE groups for four of the 10 items (Figure 2C 
and 3C and Supplementary Figure 4). Two patterns of difference were observed. The 
first type involved a positive association with age only being observed in the novel SLE 
group. The other type involved a positive association with age not being observed in the 
novel SLE group. Oral ulcers exhibited the former pattern (p=3.9x10-6), and renal 
involvement, cytopenia, and arthritis displayed the latter pattern (p>0.019). Sex-specific 
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age associations showed a third pattern: opposite associations in the novel and all SLE 
groups. Namely, cytopenia was associated with old age in the males belonging to the 
novel SLE group, while it was associated with young age in the males in the all SLE 
group. In addition, three signs showed specific associations with age in the novel SLE 
group. The frequency of serositis increased age-dependently, whereas the frequencies of 
renal involvement and arthritis showed U and inverse-U patterns, respectively. The 
detailed results of the analyses and further analyses are shown in Supplementary Note 
and Supplementary Table 4. 
 
Clustering analysis of the coexistence of signs and clinical markers in the all SLE 
and novel SLE groups 
Clustering analysis of the 11 signs in the patients in the novel SLE group 
revealed that they could be divided into two groups; namely, a group containing 
autoantibody positivity, ANA positivity, cytopenia, and arthritis and another group 
including the other 7 signs and markers (Figure 4A). The novel SLE patients (6,637) 
were also subjected to clustering analysis, which showed that they could be classified 
into 10 clusters according to their signs (Figure 4B). The sign frequencies and the 
numbers of SLE patients in each cluster are shown in Supplementary Table 5.   
 
Cluster analysis of the 10 major SLE signs (not including ANA) in the all SLE group 
showed that they could be sub-grouped into two clusters with the similar characteristics 
as those observed in the analysis of the novel SLE group although differences were 
observed among the finer cluster divisions (Figure 4C).  Cluster analysis of 10,000 
randomly selected SLE patients from the all SLE group produced 8 clear clusters 
(Figure 4D and Supplementary Table 6). The patterns of clusters partly matched those 
observed in the novel SLE group.   
 
Further analyses: Complications of SLE and the distributions of specific 
autoantibodies 
The complications of SLE were also assessed in the all SLE group, as were the effects 
of age, sex, and disease duration. The associations of autoantibodies with complications 
were assessed according to age, sex, and disease duration to assess their utility as 
predictive markers. The associations between complications and each SLE patient 




Although some small studies did not report a significant difference in age-at-onset 
between the sexes18, our large-scale study demonstrated that female patients developed 
SLE at a younger age than male patients. We evaluated the clinical features of two 
patient populations, “the novel patients”; i.e., patients who had been diagnosed with 
SLE within the last year, and “all patients”; i.e., all patients regardless of their disease 
duration. As a result, we obtained evidence of associations between SLE signs and age, 
sex, and disease duration. In our study, the frequencies of 11 major signs were similar to 
those obtained in previous reports from Asian and European countries in both the novel 
SLE and all SLE groups with the exception of serositis (25.3% in novel SLE group, 
4.6% in all SLE group; 5-22% at onset and 20-40% prevalence in previous studies)18, 
23-27. This difference might have been due to the relative difficulty of detecting serositis 
compared with other features.  
We validated previous reports of higher frequencies of serositis28, 29, renal 
involvement29, 30, and discoid eczema29-31 in males and higher frequencies of 
photosensitivity30 and oral ulcers30 in females. Although neurological involvement was 
reported to be more common in males in two previous reports32, 33, our study did not 
find any difference between the sexes. The difference between the sexes in the 
frequency of malar rash is disputed, and our study did not detect any sex difference.  
Our results indicate that any inter-sex difference in neurological involvement and malar 
rash is very small. The sex difference in the frequency of arthritis is also disputed, and 
we observed a significantly higher frequency of arthritis in females (47.0% in females 
and 36.0% in males with p=1.3x10-44). 
Only a few previous studies comprising more than 500 patients have examined the 
effects of age on the clinical manifestations of SLE 18, 28, 34, 35. Previous studies reported 
positive associations of younger age with malar rash, discoid eczema, autoantibody 
production, and photosensitivity 18, 30, and we confirmed these associations. In addition, 
we demonstrated that serositis and neurological involvement were positively associated 
with older age. Renal involvement was only associated with younger age in the novel 
SLE group.  
 No studies have ever analyzed the detailed effects of disease duration on SLE signs. 
Most of the major signs and clinical markers of SLE, especially serositis, displayed 
higher prevalences in the patients with short disease durations. Only the prevalence of 
photosensitivity increased according to disease duration. Discoid eczema was not 
associated with disease duration.  
  We performed similar analyses for more detailed signs of SLE (Supplementary 
Notes).  
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The 11 SLE signs were classified into two groups according to their 
manifestation patterns in the novel SLE group: group 1 (ANA, autoantibody positivity 
(anti-sm antibody and anti-dsDNA antibody), cytopenia, and arthritis) and group 2 
(malar rash, discoid eczema, photosensitivity, oral ulcers, neurological involvement, 
serositis, renal involvement). The first group included hematoserological abnormalities 
such as cytopenia, and arthritis was considered to be an 
inflammatory/autoimmunity-related reaction and so was classified with the 
hematoserological abnormalities due to its reduced organ specificity compared to the 
items in group 2. Therefore, we called group 1 the hematoserological group and group 2 
the organ-specific group.  In the all SLE group, such clear clustering was not very 
apparent, which might have been because individual patients tended to present various 
features during their clinical courses. 
The SLE patients in the novel SLE group were clustered into 10 groups according to the 
signs that they displayed. These groups were not associated with sex, or age (ANOVA, 
data not shown). At onset, the frequencies of the 10 groups ranged from 4.0% to 22.4%. 
The 10 groups were characterized as: represented by (1) neurological involvement 
(22.4%), (2) discoid eczema (10.6%), (3) a lack of autoantibodies other than ANA 
(12.7%), (4) oral ulcers (9.1%), (5) renal involvement (9.9%), (6) photosensitivity 
(5.7%), (7) a lack of arthritis (6.5%), (8) serositis (9.8%), (9) malar rash (4.0%), and 
(10) others (9.3%). It should be noted that each group was represented by one of the 
items in the organ-specific group or a lack of an item in the hematoserological group. 
These findings suggest that the items in the organ-specific group are the predominant 
determinants of a patient’s condition.  In the all SLE group, 8 clusters, which displayed 
frequencies ranging from 3.9 to 31.5%, were determined. The clusters were 
characterized as follows: 1) no signs or markers (6.9%), 2) cytopenia alone (5.1%), 3) 
autoantibody positivity alone (3.9%), 4) cytopenia and autoantibody positivity only 
(5.9%), 5) arthritis (9.1%), 6) renal involvement (16.4%), 7) neurological signs and 
serositis (21.3%), and 8) others (31.5%). The novel SLE and all SLE groups shared two 
clusters with similar characteristics; i.e., the “neurological signs”: and “renal 
involvement” clusters.  The reduced frequencies of signs and clinical markers observed 
in the all SLE group led to clusters based on one or no signs.  The lack of information 
about ANA during the chronic phase might also have reduced the number of clusters.  
We performed five rounds of resampling, each of which involved 10,000 patients, and 
the same clusters were maintained (data not shown). These results confirm that SLE 
patients and signs can be subgrouped into clear clusters. However, the 11 or 10 signs of 
SLE could not consistently explain the division of clusters among different stages of the 
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disease. This raised the possibility that underlying factors related to the pathology of 
SLE other than the 11 signs exist. While we analyzed the associations between clusters 
and clinical sings or complications, we could not analyze the association between 
clusters and death due to lack of information. Although the follow-up questionnaire 
included information of death causes (data not shown), this information was not filled in 
the most cases. This should be explained by the system of the nation-wide study where 
patients ask physicians to fill the questionnaire. Associations between clusters in all 
SLE group and some of complications (Supplementary Notes) suggest the possibility 
that clusters are associated with severity and prognosis of SLE.  Further follow-up 
studies would clarify the clinical characteristics of the abovementioned clusters. 
 
Finally, we would like to comment on our data source. As the primary purpose of the 
national registry is to determine whether patients qualify for public financial aid, there 
could be a bias towards the over-rating of the signs. Despite our concern about such 
overestimation, the frequencies of individual signs in our study were similar to those 
described in previous reports from Asian countries36, indicating that any over-rating was 
not too problematic. Considering the number of subjects analyzed in the current study 
and the fact that the same tendencies were observed in each year (data not shown), our 
results regarding the patterns of signs and the associations between these signs and 
gender, age, and disease duration in Japanese SLE patients should be regarded as 
conclusive. 
 
In conclusion, we have obtained conclusive evidence about the distributions of the 
clinical features of SLE and their relationships with sex, age, and age-at-onset.  
 
10 
Funding Acknowledgement. This study was supported by Grants-in-aid from the 
Ministry of Health, Labor, and Welfare of Japan  
 




1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365: 2110-21. 
2. Bengtsson C, Ohman ML, Nived O and Rantapaa Dahlqvist S. Cardiovascular 
event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 
7-year follow-up study. Lupus. 2012; 21: 452-9. 
3. Murray SG, Yazdany J, Kaiser R, et al. Cardiovascular disease and cognitive 
dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012; 64: 
1328-33. 
4. Chiu CC, Huang CC, Chan WL, et al. Increased risk of ischemic stroke in patients 
with systemic lupus erythematosus: a nationwide population-based study. Intern Med. 2012; 
51: 17-21. 
5. Hochberg MC. Updating the American College of Rheumatology revised criteria for 
the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725. 
6. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic 
Lupus International Collaborating Clinics classification criteria for systemic lupus 
erythematosus. Arthritis Rheum. 2012; 64: 2677-86. 
7. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the 
United States: results from the third national health and nutrition examination survey. J 
Womens Health (Larchmt). 2004; 13: 713-8. 
8. Amor B, Bouchet H and Delrieu F. [National survey on reactive arthritis by the 
French Society of Rheumatology]. Rev Rhum Mal Osteoartic. 1983; 50: 733-43. 
9. Gudmundsson S and Steinsson K. Systemic lupus erythematosus in Iceland 1975 
through 1984. A nationwide epidemiological study in an unselected population. J Rheumatol. 
1990; 17: 1162-7. 
10. Somers EC, Thomas SL, Smeeth L, Schoonen WM and Hall AJ. Incidence of 
systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum. 2007; 
57: 612-8. 
11. Helve T. Prevalence and mortality rates of systemic lupus erythematosus and 
causes of death in SLE patients in Finland. Scand J Rheumatol. 1985; 14: 43-6. 
12. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of 
11 
systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the 
US Medicaid beneficiary population. Arthritis Rheum. 2012; 64: 2669-76. 
13. Chiu YM and Lai CH. Nationwide population-based epidemiologic study of 
systemic lupus erythematosus in Taiwan. Lupus. 2010; 19: 1250-5. 
14. Ohta A, Nagai M, Nishina M, Tomimitsu H and Kohsaka H. Age at onset and 
gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and 
systemic sclerosis in Japan. Modern rheumatology / the Japan Rheumatism Association. 
2012. 
15. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L and Cooper GS. Understanding 
the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 
2010; 39: 257-68. 
16. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin 
Rheumatol. 1999; 11: 352-6. 
17. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH and Weisman MH. Review: Male 
systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2010; 19: 
119-29. 
18. Feng JB, Ni JD, Yao X, et al. Gender and age influence on clinical and laboratory 
features in Chinese patients with systemic lupus erythematosus: 1,790 cases. Rheumatol Int. 
2010; 30: 1017-23. 
19. Levy DM, Peschken CA, Tucker LB, et al. Influence of ethnicity on childhood-onset 
systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. 
Arthritis Care Res (Hoboken). 2013; 65: 152-60. 
20. Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients 
with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical 
subsets. Clin Rheumatol. 1998; 17: 468-77. 
21. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin 
American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: 
ethnic and disease heterogeneity among "Hispanics". Medicine. 2004; 83: 1-17. 
22. Ballou SP, Khan MA and Kushner I. Clinical features of systemic lupus 
erythematosus: differences related to race and age of onset. Arthritis Rheum. 1982; 25: 
55-60. 
23. Wang F, Wang CL, Tan CT and Manivasagar M. Systemic lupus erythematosus in 
Malaysia: a study of 539 patients and comparison of prevalence and disease expression in 
different racial and gender groups. Lupus. 1997; 6: 248-53. 
24. Tan TC, Fang H, Magder LS and Petri MA. Differences between male and female 
systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012; 39: 759-69. 
12 
25. Garcia MA, Marcos JC, Marcos AI, et al. Male systemic lupus erythematosus in a 
Latin-American inception cohort of 1214 patients. Lupus. 2005; 14: 938-46. 
26. Malaviya AN, Chandrasekaran AN, Kumar A and Shamar PN. Systemic lupus 
erythematosus in India. Lupus. 1997; 6: 690-700. 
27. Chahade WH, Sato EI, Moura JE, Jr., Costallat LT and Andrade LE. Systemic 
lupus erythematosus in Sao Paulo/Brazil: a clinical and laboratory overview. Lupus. 1995; 4: 
100-3. 
28. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical 
and immunologic patterns of disease expression in a cohort of 1,000 patients. The European 
Working Party on Systemic Lupus Erythematosus. Medicine. 1993; 72: 113-24. 
29. Soto ME, Vallejo M, Guillen F, Simon JA, Arena E and Reyes PA. Gender impact in 
systemic lupus erythematosus. Clin Exp Rheumatol. 2004; 22: 713-21. 
30. Voulgari PV, Katsimbri P, Alamanos Y and Drosos AA. Gender and age differences 
in systemic lupus erythematosus. A study of 489 Greek patients with a review of the 
literature. Lupus. 2002; 11: 722-9. 
31. Font J, Cervera R, Navarro M, et al. Systemic lupus erythematosus in men: clinical 
and immunological characteristics. Ann Rheum Dis. 1992; 51: 1050-2. 
32. Stefanidou S, Benos A, Galanopoulou V, et al. Clinical expression and morbidity of 
systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female 
comparison. Lupus. 2011; 20: 1090-4. 
33. Mok CC, To CH, Ho LY and Yu KL. Incidence and mortality of systemic lupus 
erythematosus in a southern Chinese population, 2000-2006. J Rheumatol. 2008; 35: 
1978-82. 
34. Ward MM and Polisson RP. A meta-analysis of the clinical manifestations of 
older-onset systemic lupus erythematosus. Arthritis Rheum. 1989; 32: 1226-32. 
35. Lalani S, Pope J, de Leon F and Peschken C. Clinical features and prognosis of 
late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J 
Rheumatol. 2010; 37: 38-44. 
36. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV and Kwon N. Systematic 
review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: 
prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012; 
64: 159-68. 
 
Figure 1. Distribution of patients who developed SLE  
A) Distribution of the current ages of the SLE patients. 
B) Distribution of the age-at-onset of the SLE patients.  
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Figure 2. Distribution and clusters of SLE signs and patients in the all SLE group 
A) Frequency of SLE signs in a year. 
Frequencies of SLE signs according to sex (B), age (C), and disease duration (D). 
*p-value<10-5, **p-value<10-10 
 
Figure 3. Distribution and clusters of SLE signs and patients in the novel SLE group 
A) Frequencies of SLE signs during the first year after diagnosis. 
Frequency of SLE signs within a year of diagnosis according to sex (B) and age (C) 
based on multiple logistic linear regression analysis. *p-value<10-5, **p-value<10-10 
 
Figure 4. Clusters of SLE signs and patients. 
A) Clustering of 11 SLE major signs in patients that had been diagnosed with SLE 
within the last year. 
B) Clustering of 6637 SLE patients that had been diagnosed with SLE within the last 
year. 
C) Clustering of 10 major SLE signs in the all SLE group. 









To further assess the signs and clinical markers of SLE, we performed the 
detailed analyses outlined below. 
 
Association studies to analyze the effects of age, sex, and disease duration on 
sign frequency were performed in the all SLE group. The resultant frequency data are 
shown in Supplementary Table 2. The association studies revealed that disease duration 
had a strong influence on sign frequency except for that of anti-phospholipid (APS) 
antibodies (Supplementary Table 3 and Supplementary Figure 3). 
 
When we analyzed the detailed signs of SLE in the novel SLE group, we found 
that lymphopenia was the most common sign (Supplementary Table 2). More than half 
of the patients demonstrated anti-SS-A antibody positivity, leukopenia, and arthritis 
(Supplementary Table 2). When we analyzed the associations of age and sex with the 
detailed signs of SLE, we found that anti-SS-A antibody positivity, anti-SS-B antibody 
positivity, anti-U1RNP antibody positivity, Raynaud’s phenomenon, leukopenia, and 
alopecia are frequently observed in female SLE patients, whereas pleuritis, interstitial 
pneumonia, thrombocytopenia, psychiatric signs, and pulmonary hemorrhaging are 
more frequently observed in male patients (Supplementary Figure 4 and Supplementary 
Table 4). 
 
Next, we analyzed the prevalence of severe complications in patients with SLE, 
including infection, compression fractures of bone, gastric ulcers, bone necrosis, 
myocardial infarction, and cerebral infarction (Supplementary Table 7). We also 
analyzed the correlations between these complications and age, sex, and disease 
duration using multiple logistic regression analysis. As a result, we found that the 
contributions of age, sex, and disease duration to the development of severe 
complications differed greatly among the complications (Supplementary Figure 6). We 
found that bone necrosis is most likely to occur in young patients, while bone fractures 
tend to occur in older patients. We also analyzed whether complications are associated 
with particular clusters of patients in the all SLE group using ANOVA. Differences 
among the clusters were found for all complications, except bone necrosis and 




Supplementary Figure 1. Effects of sex, age, and disease duration on the major signs 
and markers of SLE in the all SLE group 
Results of multiple logistic regression analysis of the annual frequencies of the 10 major 
signs of SLE in the all SLE group are shown for A) sex, B) age, C) disease duration, D) 
age in males and females, E) and disease duration in males and females. The vertical 
axes indicate odds ratios, and the lines indicate 95% confidence intervals. Odds ratio are 
indicated for subjects of 10 years for age with a disease duration of five years. The blue 
and red lines indicate males and females, respectively. 
 
Supplementary Figure 2. Detailed signs of SLE in the all SLE group 
Annual distributions of the detailed signs of SLE in the all SLE group according to A) 
sex, B) age, and C) disease duration. Results of multiple logistic regression analysis of 
the signs are shown for D) sex, E) age, F) disease duration, G) age in males and females, 
H) and disease duration in males and females. The vertical axes indicate odds ratios, and 
the lines indicate 95% confidence intervals. Odds ratios are shown for individuals of 10 
years for age with a disease duration of five years. The blue and red lines indicate males 
and females, respectively. *p-value<10-5, **p-value<10-10 
 
Supplementary Figure 3. Effects of sex and age on signs and markers of SLE in the 
novel SLE group 
Results of multiple logistic regression analysis of the 10 major signs of SLE are shown 
for A) sex and B) age. The results for the all SLE group are shown in deep red. C) 
Effects of age in males and females according to single logistic regression analysis. D) 
Distributions of the detailed signs according to sex. Multiple logistic regression analysis 
of the detailed signs according to E) sex and F) age. The results for the all SLE group 
are shown in deep red, if available. G) Effects of age on the frequencies of the detailed 
signs in males and females. 
Detailed signs that displayed frequencies of greater than 5% are indicated. 
*p-value<10-5, **p-value<10-10 
 
Supplementary Figure 4. Heat map of SLE patients and the 11 items for SLE in the 
novel SLE group 
 
Supplementary Figure 5. Annual distribution of complications in the all SLE group 
A) Incidences of complications in the all SLE group. 




Supplementary Figure 6. Effects of APS antibody-related signs on cerebral and 
myocardial infarction. 
A) Dose-dependent increase in the risk of cerebral infarction associated with APS 
autoantibodies. 
B) Dose-dependent increase in the risk of acute myocardial infarction associated with 
APS autoantibodies.  




Supplementary Table 1.Clinical information collected in the novel and follow-up registries and 
converted into text files. 
  Novel Follow-up 
Year of application ○ ○ 
Novel or Follow-up registry ○ ○ 
Sex ○ ○ 
Year of Birth ○ ○ 
Current prefectural address ○ ○ 
Prefecture at birth ○ ○ 
Current Age ○ ○ 
Prefecture at onset ○ ○ 
Time of onset (yyyy/mm) ○ ○ 
Age at onset ○ ○ 
Time of first visit ○ ○ 
Information of insurance ○ ○ 
Information of disability ○ ○ 
qualify of disability, grade ○ ○ 
time of qualification 
 
○ 
Social activity status ○ ○ 
unspecified family history ○ 
 
information of family affected ○ 
 
Frequency of hospital visit ○ ○ 
   Detailed items for cytopenia 
  
Hemolytic anemia ○ ○ 
Leukopenia ○ ○ 
Lymphopenia ○ ○ 
Thrombocytopenia ○ ○ 
Detailed items for autoantibodies 
  
Anti-nuclear antibody ○ 
 
Anti-dsDNA antibody ○ ○ 
Anti-sm antibody ○ ○ 
Anti-RNP antibody ○ 
 
Anti-SSA antibody ○ 
 
Anti-SSB antibody ○ 
 
Detailed items for anti-phospholipid syndrome  
 
4 
Anti-cardiolipin antibody ○ ○ 
Lupus anticoagulant ○ ○ 




Detailed items related with renal dysfunction  
 
Rapid progressive glomerulonephritis ○ 
 
Acute renal failure ○ 
 




Renal biopsy WHO class ○ ○ 
Protein urea ○ 
 




serum creatinine ○ 
 
CH50 level ○ 
 
C3 level ○ 
 











Organic brain syndrome ○ 
 
Cranial nerve sign ○ 
 
Multiple mononeuritis ○ 
 
Disturbance of consciousness ○ 
 
Cerebral vascular disorder ○ 
 
Spinal cord lesion ○ 
 
Aseptic meningitis ○ 
 
Serositis ○ ○ 






Interstitial pneumoniae ○ 
 
Pulmonary hypertension ○ 
 
Pulmonary thrombosis ○ 
 
Pulmonary hemorrhage ○ 
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Detailed items related to skin signs 
  
Photosensitivity ○ ○ 
Malar rash ○ ○ 
Oral ulcer ○ ○ 
Discoid eczema ○ ○ 
Alopecia ○ 
 
Raynaud's phenomenon ○ 
 
Detailed items related to musculoskeletal signs  
 
Arthritis ○ ○ 
Myalgia ○ 
 
Muscle weakness ○ 
 
   Differential diagnosis:Whether or not the patients'  
symptoms and signs are explained by: 
  
Other connective tissue diseases ○ 
 








   Treatment:Usage, period and effect of 
  
Corticosteroid ○ ○ 
NSAIDs ○ ○ 
steroid pulse ○ ○ 
immunosuppressant ○ ○ 
Plasma exchange ○ ○ 
Plasma apheresis ○ ○ 
Others ○ ○ 
   Complications: 
  
Myocardial infarction ○ ○ 
Cerebral infarction ○ ○ 
Peptic ulcer ○ ○ 
Bone fracture ○ ○ 
Bone necrosis ○ ○ 
Infection ○ ○ 
Diabetes mellitus ○ ○ 
6 
hypertension ○ ○ 
malignancy ○ ○ 
DIC ○ ○ 
others ○ ○ 
 
 
Supplementary Table 2. Frequency of SLE signs and markers in the SLE groups 
 
Novel group All SLE 
  Number of patients Positivity rate Number of patients 
Positivity 
rate 
Major 11 signs of SLE 
    
Anti-nuclear antibody 8970 98.4% NA NA 
Cytopenia 9275 90.0% 41761 61.0% 
Autoantibodies 9205 83.9% 40164 55.8% 
Arthritis 9254 64.7% 41600 45.8% 
Photosensitivity 9255 36.6% 41211 43.4% 
Malar rash 9313 43.0% 41766 31.3% 
Renal involvement 8736 40.4% 40967 20.9% 
Oral ulcer 9235 22.9% 41593 13.4% 
Discoid eczema 9283 17.0% 41659 12.4% 
Neurological signs 9295 8.8% 41009 8.0% 
Serositis 9241 25.3% 41312 4.6% 
Detailed items for cytopenia 
    
Hemolytic anemia 7667 12.8% 41076 3.5% 
Leukopenia 9259 56.9% 41592 26.7% 
Lymphopenia 8861 86.8% 41163 56.6% 
Thrombocytopenia 9228 20.4% 41475 9.6% 
Detailed items for autoantibodies 
    
Anti-dsDNA antibody 7901 76.9% 39323 46.2% 
Anti-sm antibody 7912 36.4% 29066 18.5% 
Anti-RNP antibody 7178 42.0% NA NA 
Anti-SSA antibody 7387 55.7% NA NA 
Anti-SSB antibody 6582 18.3% NA NA 
Detailed items for anti-phospholipid syndrome 
    
Anti-cardiolipin antibody 6603 28.0% 25384 17.8% 
Lupus anticoagulant 5259 22.2% 21044 13.0% 
7 
Biological false-positive for syphilis 6237 11.1% 19739 6.0% 
Detailed items related with renal dysfunction 
    
Rapid progressive glomerulonephritis 9099 8.1% NA NA 
Acute renal failure 9110 6.3% NA NA 
Chronic renal failure 9105 4.4% NA NA 
Nephrosis 9111 16.1% NA NA 
Detailed items related to psychoneurological signs 
    
Seizure 9287 2.2% NA NA 
Psychosis 9256 7.5% NA NA 
Organic brain syndrome 9243 1.9% NA NA 
Cranial nerve sign 9247 2.3% NA NA 
Multiple mononeuritis 9200 4.7% NA NA 
Disturbance of consciousness 9196 4.5% NA NA 
Cerebral vascular disorder 9188 4.5% NA NA 
Spinal cord lesion 9187 0.5% NA NA 
Aseptic meningitis 9176 1.6% NA NA 
Detailed items related to cardiopulmonary signs 
    
Pleuritis 9217 20.7% NA NA 
Pericarditis 9186 14.2% NA NA 
Interstitial pneumoniae 9181 7.6% NA NA 
Pulmonary hypertension 9074 2.5% NA NA 
Pulmonary thrombosis 9143 0.9% NA NA 
Pulmonary hemorrhage 9149 0.8% NA NA 
Detailed items related to skin signs 
    
Alopecia 9189 24.9% NA NA 
Raynaud's phenomenon 9162 26.9% NA NA 
Detailed items related to musculoskeletal signs 
    
Myalgia 9143 30.8% NA NA 
Muscle weakness 9110 20.6% NA NA 
 
 
Supplementary Table 3. Multiple logistic regression analysis of the effects of sex, age, and disease 
duration on the frequencies of SLE signs and markers in the all SLE group 
 
Sex Age Duration 
 
p OR p OR p OR 
Cytopenia 9.4x10-20 1.44 (1.33-1.55) 1.5 x10-22 0.92 (0.91-0.94) 9.6 x10-87 0.88 (0.87-0.89) 
8 
Autoantibodies 0.032 1.09 (1.01-1.18) 1.9 x10-101 0.83 (0.82-0.85) 4.7 x10-122 0.85 (0.84-0.86) 
Arthritis 3.9 x10-41 1.73 (1.6-1.87) 3.4 x10-40 1.12 (1.10-1.13) 3.1 x10-40 0.92 (0.91-0.93) 
Photosensitivity 6.4 x10-23 1.50 (1.38-1.63) 2.7 x10-25 0.92 (0.90-0.93) 2.3 x10-26 1.07 (1.06-1.09) 
Malar rash 0.22 1.05 (0.97-1.15) 2.8 x10-107 0.82 (0.80-0.83) 0.036 0.99 (0.97-1.00) 
Renal involvement 9.1 x10-57 0.51 (0.47-0.55) 2.6 x10-26 0.90 (0.88-0.92) 0.0057 0.98 (0.96-0.99) 
Oral ulcer 1.4 x10-10 1.51 (1.33-1.71) 0.91 1.00 (0.98-1.02) 2.4 x10-8 0.95 (0.93-0.97) 
Discoid eczema 5.7 x10-7 0.76 (0.68-0.85) 3.8 x10-21 0.89 (0.87-0.91) 0.77 1.00 (0.98-1.02) 
Neurological signs 0.79 1.02 (0.89-1.17) 2.1 x10-9 1.09 (1.06-1.12) 1.7 x10-6 0.94 (0.92-0.97) 
Serositis 0.00014 0.75 (0.65-0.87) 6.4 x10-37 1.23 (1.19-1.27) 1.8 x10-137 0.60 (0.57-0.62) 
Hemolytic anemia 0.26 0.90 (0.75-1.08) 0.85 1.00 (0.97-1.04) 3.3 x10-38 0.77 (0.74-0.80) 
Leukocytopenia 5.8 x10-19 1.51 (1.38-1.65) 7.8 x10-13 0.94 (0.92-0.95) 1.1 x10-104 0.84 (0.83-0.86) 
Lymphopenia 3.6 x10-14 1.35 (1.25-1.46) 1.9 x10-32 0.90 (0.89-0.92) 3.3 x10-86 0.88 (0.87-0.89) 
Thrombocytopenia 0.76 0.98 (0.87-1.11) 1.2 x10-5 1.06 (1.03-1.09) 5.1 x10-26 0.89 (0.87-0.91) 
Anti-dsDNA 
antibody 
0.00027 1.16 (1.07-1.26) 7.2 x10-97 0.83 (0.82-0.85) 9.4 x10-118 0.85 (0.84-0.86) 
Anti-sm antibody 0.29 1.06 (0.95-1.19) 1.3 x10-42 0.85 (0.83-0.87) 4.1 x10-76 0.81 (0.79-0.83) 
Anti-cardiolipin 
antibody 
0.0014 0.82 (0.73-0.93) 2.6 x10-6 0.94 (0.91-0.96) 0.33 1.01 (0.99-1.03) 








Supplementary Table 4. Effects of age and sex on the frequency of SLE signs and markers in the 
novel SLE group 
 
Sex (Female) Age (/10 years) 
 
p OR p OR 
Cytopenia 0.53 1.06 (0.88-1.27) 0.80 1.00 (0.96-1.03) 
Autoantibodies 0.099 0.88 (0.75-1.02) 2.0 x10-6 0.93 (0.90-0.96) 
Arthritis 5.7x10-22 1.73 (1.55-1.94) 0.13 1.02 (0.99-1.04) 
Photosensitivity 2.8 x10-13 1.58 (1.39-1.78) 8.6 x10-13 0.92 (0.89-0.94) 
Malar rash 0.18 1.08 (0.96-1.22) 1.1 x10-133 0.73 (0.71-0.75) 
Renal involvement 8.2 x10-22 0.57 (0.51-0.64) 0.019 1.03 (1.00-1.05) 
Oral ulcer 5.5 x10-5 1.33 (1.16-1.54) 3.9 x10-6 0.94 (0.91-0.96) 
Discoid eczema 1.1 x10-5 0.73 (0.63-0.84) 6.9 x10-20 0.87 (0.84-0.89) 
Neurological signs 0.23 0.89 (0.74-1.08) 1.0 x10-11 1.14 (1.10-1.19) 
Serositis 1.7 x10-12 0.65 (0.58-0.73) 1.5 x10-54 1.23 (1.20-1.26) 
Hemolytic anemia 0.34 0.92 (0.77-1.10) 0.015 1.05 (1.01-1.09) 
Leukopenia 6.6 x10-5 1.25 (1.12-1.40) 6.9 x10-16 0.91 (0.89-0.93) 
Lymphopenia 0.0782 1.16 (0.98-1.36) 0.18 1.02 (0.99-1.06) 
Thrombocytopenia 7.1 x10-9 0.69 (0.60-0.78) 1.6 x10-8 1.08 (1.05-1.11) 
Anti-dsDNA antibody 0.91 1.01 (0.88-1.16) 0.014 0.96 (0.94-0.99) 
Anti-sm antibody 0.37 1.06 (0.93-1.21) 5.5 x10-54 0.81 (0.79-0.83) 
Anti-RNP antibody 4.7 x10-8 1.46 (1.27-1.66) 2.9 x10-46 0.82 (0.80-0.84) 
Anti-SSA antibody 6.3 x10-22 1.86 (1.64-2.11) 2.7 x10-16 0.90 (0.87-0.92) 
Anti-SSB antibody 3.3 x10-7 1.65 (1.36-2.01) 0.0012 0.94 (0.91-0.98) 
Anti-cardiolipin 
antibody 
0.066 0.87 (0.76-1.01) 1.00 1.00 (0.97-1.03) 
Lupus anticoagulant 0.37 0.92 (0.78-1.10) 5.4 x10-7 0.91 (0.88-0.94) 
Biological false-positive 
for syphilis 
0.10 1.21 (0.96-1.52) 4.9 x10-14 0.83 (0.80-0.87) 
Rapid progressive 
glomerulonephritis 
2.0 x10-9 0.57 (0.48-0.69) 0.025 0.95 (0.92-0.99) 
Acute renal failure 1.5 x10-11 0.51 (0.42-0.62) 0.31 1.02 (0.98-1.07) 
Nephrosis 1.6 x10-4 0.76 (0.66-0.87) 0.039 0.97 (0.94-1.00) 
Psychosis 0.35 0.91 (0.75-1.11) 7.7 x10-15 1.18 (1.13-1.23) 
Pleuritis 1.6 x10-13 0.62 (0.55-0.70) 6.8 x10-57 1.25 (1.22-1.29) 
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Pericarditis 0.14 0.89 (0.77-1.04) 2.3 x10-17 1.15 (1.11-1.18) 
Interstitial pneumonia 4.1 x10-5 0.68 (0.57-0.82) 6.7 x10-62 1.44 (1.38-1.50) 
Alopecia 2.0 x10-9 1.53 (1.33-1.76) 0.014 0.97 (0.94-0.99) 
Raynaud's phenomenon 5.8 x10-25 2.13 (1.85-2.46) 6.0 x10-5 1.05 (1.03-1.08) 
Myalgia 0.33 1.06 (0.94-1.20) 0.0068 1.03 (1.01-1.06) 





















1 0.62 0.17 0.3 0.5 0.42 0.9 0.72 1 0.33 0.33 0.58 
1490 
(22.4%) 
2 0.57 0.9 0.25 0.63 0.47 0.97 0.99 0.87 0.26 0.01 0.05 
703 
(10.6%) 
3 0.63 0.21 0.24 0.47 0.42 0.01 0.99 0.99 0.25 0.09 0.25 
840 
(12.7%) 
4 0.7 0.01 1 0.45 0.42 1 1 1 0.27 0 0 
607 
(9.1%) 
5 0.52 0 0 0.33 0.22 1 1 1 1 0 0 
658 
(9.9%) 
6 1 0 0 0.43 1 1 1 1 0 0 0 
378 
(5.7%) 
7 0 0 0 0.55 0.37 1 1 1 0 0 0 
429 
(6.5%) 
8 0.48 0 0 0 0 1 1 1 0.37 0 1 
650 
(9.8%) 
9 1 0 0 1 0 1 1 1 0 0 0 
263 
(4%) 






















1 0.57 0.2 0.55 0.36 0.5 0.65 0.61 0.19 0.4 0.26 
2129 
(21.3%) 
2 0 0 0 0 0 0 0 0 0 0 
687 
(6.9%) 
3 0.43 0.14 0.11 0.37 0.46 0.64 0.62 0.99 0.01 0.04 
1641 
(16.4%) 
4 0 0 0 0 0 1 0 0 0 0 
390 
(3.9%) 
5 0 0 0 0 0 1 1 0 0 0 
590 
(5.9%) 
6 0.49 0.21 0 0.55 0.78 0.54 0.62 0 0 0 
3151 
(31.5%) 
7 0 0 0 0 0 0 1 0 0 0 
507 
(5.1%) 










Sex Age Duration ANOVA 
p-value P OR p OR p OR 
Myocardial 
infarction 
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Supplementary Figure 6
